Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: News

US Anesthesia Drugs and Devices Market Set to Reach $6.83 Billion in 2023, Driven by Growing Healthcare Expenditure – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “The US Anesthesia Drugs and Devices Market (by segment, Type, Drug Product, & Device Product): Insights and Forecast with Potential Impact of COVID-19 (2022-2027)” report has been added to ResearchAndMarkets.com’s offering.


The US anesthesia drugs and devices market is poised for significant growth, with a projected value of US$6.83 billion in 2023, experiencing a robust CAGR of 6.78% during the forecasted period. Anesthesia, the use of drugs to alleviate pain during medical procedures, is essential in the healthcare industry and is administered through various means such as injection, inhalation, topical application, and more.

Market Segmentation

The US anesthesia drugs and devices market is divided into two primary segments: anesthesia drugs and anesthesia devices. Among these segments, anesthesia drugs currently hold the majority share, while the anesthesia devices segment is expected to experience substantial growth due to increased healthcare expenditure in the region.

Types and Products

In terms of types, the US anesthesia drugs market is categorized into General, Local, and other anesthesia. The General anesthesia drug segment dominates the market, followed by local anesthesia drugs. The development of novel anesthesia drugs through pharmaceutical R&D is expected to create growth opportunities in the “other anesthesia drugs” segment.

When considering device products, the market is segmented into advanced, basic, and integrated anesthesia devices. The advanced segment holds the largest share in the market, followed by integrated anesthesia devices. Ongoing advancements in anesthesia monitoring devices and the demand for improved monitoring contribute to the growth of the advanced anesthesia monitoring devices market.

The market is further categorized by drug product into Bupivacaine, Ropivacaine, Lidocaine, Chloroprocaine, Prilocaine, Benzocaine, and other local anesthetics. Lidocaine anesthesia drugs have the highest market share, followed by Bupivacaine and Ropivacaine. The market is anticipated to grow due to increasing patient populations and a rise in medical and surgical procedures.

Key Drivers and Challenges

Driver: Increase in Monitored Anesthesia Use

The adoption of Monitored Anesthesia Care (MAC) is on the rise. MAC involves specific anesthesia services for procedures performed under local anesthesia with sedation and analgesia, allowing patients to maintain consciousness. Patients are opting for monitored anesthesia to ensure satisfaction during surgeries, leading to increased usage of anesthesia equipment and drugs.

Challenge: Side Effects of Anesthesia

While anesthesia is generally administered by anesthesiologists, it can sometimes lead to side effects, including nausea, headache, vomiting, and shivering, among others. General anesthetics can affect the central nervous system, causing drowsiness and coordination problems. These side effects can deter some patients and impact the growth of the anesthesiology market.

Trend: Growth of Ambulatory Surgical Centers (ASC)

The establishment of ambulatory surgical centers (ASCs) is escalating due to an aging population and the prevalence of chronic diseases. ASCs offer improved reimbursement and a reduced risk of healthcare-associated infections, attracting more patients. This growth in ASCs is driving the demand for anesthesia drugs and devices.

COVID-19 Analysis

The COVID-19 pandemic led to increased utilization of intensive care unit (ICU) ventilators and anesthesia machines for longer-term ventilation. Anesthesia drugs were used during longer-term ventilation with anesthesia machines. Initially, anesthesia drug demand decreased in 2020 due to postponed or canceled surgeries. However, as elective surgeries resumed, anesthesia drug consumption increased.

Key Players

The US anesthesia drugs and devices market is competitive and features several major players, including Baxter International Inc., Envision Healthcare Corporation (KKR & Co. Inc.), Becton, Dickinson and Company, TeamHealth (Blackstone), Teleflex Incorporated, Dragerwerk AG & Co. KGaA, B. Braun Avitum AG (Braun), 3M Company, Abbvie Inc., AstraZeneca Plc, Abbott Laboratories, ICU Medical, Inc., SunMed LLC, and General Electric Company.

Top Impacting Factors

Growth Drivers

  • Rising Geriatric Population
  • Growing Healthcare Expenditure
  • Increase in Monitored Anesthesia Use
  • Increase In Number Of Approval For Anesthesia Drugs

Challenges

  • Side Effects of Anesthesia
  • Lack of Skilled Anesthesiologist

Trends

  • Escalating Establishment of Ambulatory Surgical Centers (ASC)
  • Technological Enhancement of Anesthesia Devices

For more information about this report visit https://www.researchandmarkets.com/r/tnbekz

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Staff

Recent Posts

Fine Rituals Announces Major Category Expansion into Functional Foods; Reports 150% Sales Surge Amidst Growing Demand for “Resilient Wellness”

Tel Aviv, Israel--(Newsfile Corp. - March 30, 2026) - Fine Rituals, Israel's premier brand architect…

4 hours ago

Mesirow Launches Redesigned mesirow.com to Elevate Digital Experience and Access to Firm Expertise

New site supports Mesirow's ongoing growth, innovation, and commitment to investing in what matters.Launch showcases…

8 hours ago

NUGEN Audio CEO Dr. Paul Tapper to Lead Presentation About Dialog Intelligibility and Loudness at NAB 2026

LAS VEGAS, MARCH 30, 2026 ― Dr. Paul Tapper, CEO of NUGEN Audio, will lead…

18 hours ago

CSPi Technology Solutions Recognized on CRN’s 2026 MSP 500 List

BOCA RATON, FL / ACCESS Newswire / March 30, 2026 / CSPi Technology Solutions (NASDAQ:CSPI),…

21 hours ago

DrumBot AI Launches the First Drum Machine that Listens, Learns and Talks Back

WINNIPEG, MB / ACCESS Newswire / March 30, 2026 / DrumBot AI has launched a…

21 hours ago

Numeracle Urges FCC to Mandate Verified Caller Identity to Combat Impersonation Fraud

MCLEAN, VA / ACCESS Newswire / March 30, 2026 / Numeracle™ Inc., (Numeracle) the pioneer…

21 hours ago